GB virus C and methods of treating viral infections
AssigneesUniversity of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
InventorsJack Stapleton, Jinhua Xiang, Sarah George
Life of this patent
Estimating the term…
Abstract
The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.
Claims34
An isolated and purified nucleic acid molecule encoding an infectious GBV-C, wherein the nucleic acid molecule encodes SEQ ID NO:20, or a variant thereof.
An isolated and purified infectious GBV-C comprising a nucleic acid that encodes SEQ ID NO:20 or a variant thereof.
A host cell comprising a nucleic acid molecule encoding an infectious GBV-C, wherein the nucleic acid molecule encodes SEQ ID NO:20, or a variant thereof.
A method of inhibiting HIV disease progression in a subject infected with HIV comprising administering to the subject an effective amount of an isolated and purified nucleic acid molecule encoding an infectious GBV-C sequence, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant thereof.
A method of inhibiting HIV disease progression in a subject infected with HIV comprising administering to the subject an effective amount of an isolated and purified infectious GBV-C comprising a nucleic acid molecule, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant thereof.
A method of inhibiting HIV infection in a subject comprising administering to the subject an effective amount of an isolated and purified nucleic acid molecule encoding an infectious GBV-C, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant thereof.
A method of inhibiting HIV infection in a CD4+ cell comprising contacting the cell with an effective amount of an isolated and purified nucleic acid molecule encoding an infectious GBV-C, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant thereof.
A method of inhibiting a HIV replication in a cell comprising contacting the cell with an effective amount of an isolated and purified nucleic acid molecule, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant thereof, in an amount effective to inhibit HIV replication in the cell.
A method of treating a subject infected with HIV comprising administering to a cell of the subject an effective amount of an infectious GBV-C, wherein the GBV-C comprises a nucleic acid sequence encoding SEQ ID NO:20 or a variant thereof, and a heterologous nucleic acid sequence.
A method of expressing a heterologous nucleic acid sequence comprising providing to a cell an isolated and purified nucleic acid construct comprising an infectious GBV-C comprising a nucleic acid molecule, wherein the nucleic acid molecule encodes SEQ ID NO:20 or a variant therefor, and the heterologous nucleic acid sequence.
A method of inducing an immune response in a subject comprising administering to the subject an amount of an expression construct comprising a GBV-C nucleic acid sequence, wherein the sequence encodes SEQ ID NO:20 or a variant thereof, and a heterologous nucleic acid sequence operably linked to a promoter, wherein the heterologous nucleic acid sequence encodes a polypeptide, effective to elicit an immune response against the polypeptide.
An isolated and purified nucleic acid molecule comprising SEQ ID NO:19 or a variant thereof.
Dependencies are inferred from the claim text.